drugset / Trial / NCT03206138

Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod.

NCT03206138

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a study to investigate the safety and efficacy of GX-188E administered IM plus local administration of GX-I7 or Imiquimod at cervix in subjects with cervical intraepithelial neoplasia (CIN) 3.

Timeline

Start
2017-05-30
Primary completion
2018-10
Completion
2018-10

Drugs

EvaluationDrugModalityDoseRoute
Subject GX-188E Vaccine 1 mg Intramuscular
Subject Imiquimod Other / unclassified 12.5 mg Topical
Subject NT-I7 Protein / enzyme biologic 3 mg Other